Table 1 Characteristics of some metabolic pathway blockers in influenza infection
From: Metabolic host response and therapeutic approaches to influenza infection
Agent | Target | Outcome | Model | Reference |
|---|---|---|---|---|
BEZ235 | PI3K/mTOR | Reconstitution of metabolic status and decreased viral replication | In vivo | [9] |
Hochuekkito | Effect on mitochondrial and glycolysis | Ameliorates metabolism and intensifies the symptoms | In vitro | [160] |
Simvastatin | Sterol synthesis | Decreased influenza replication and cytokine production | In vitro | [161] |
DADA | Pyruvate dehydrogenase kinase | Suppresses cytokine storm and viral replication | In vivo | [94] |
MJWQH | amino acid, fatty acid and arachidonic acid pathway | Improved weight loss, lung index, biomarkers and inflammatory mediators such as prostaglandin E2 | In vivo | [162] |
Bezafibrate | Carnitine palmitoyltransferase II | Restores the ATP levels in cells and intensifies the symptoms | In vivo | [110] |
AM580 | Sterol regulatory element binding protein (SREBP) pathways | Inhibited influenza virus replication through interference with SREBP paths | In vivo | [105] |